Letters to the Editor

Should Perindopril Be Used to Treat Patients with Heart Failure?



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2002 May 1;65(9):1742-1752.

to the editor: We read with great interest the review article entitled “Spironolactone in Left-Sided Heart Failure: How Does it Fit in?”1 However, we were surprised by the notable omission of perindopril (Aceon) in Table 4 (“Agents used to decrease mortality in patients with heart failure”) and by the equally notable appearance of moexipril (Univasc) in the context of heart failure. The majority of review articles relating to pharmacotherapy that have appeared in American Family Physician are balanced and accurate; although the review by Margo and colleagues1 is generally informative, we feel that a brief comment is warranted.

A thorough review of the biomedical literature (Ovid Technologies, Medline 1963 through September 2001) regarding the role of moexipril in heart failure yields a single citation of moexipril use in induced ischemic heart failure in rats.2 Conversely, although perindopril is not labeled by the U.S. Food and Drug Administration for the treatment of congestive heart failure, its ability to ameliorate mild to moderate or severe3 heart failure4 of both ischemic and nonischemic origin is well established in fairly large randomized placebo-controlled trials. Further, determining the most effective angiotensin-converting enzyme (ACE) inhibitor in heart failure requires a critical assessment of these data because the biology of ACE inhibition in the setting of heart failure5 varies within the ACE-inhibitor drug class.6

We agree with the authors1 that spironolactone can be beneficial in improving the neurohormonal and biophysical properties of the peripheral vasculature in the physiopathology of heart failure, and may exhibit synergy with tissue type ACE inhibitors. However, the disparity in the evidence base for individual ACE inhibitors should be considered by authors and practicing physicians.

Dr. Perdikis is a member of the Lecture Bureau for Solvay Pharmaceuticals.

REFERENCES

1. Margo KL, Luttermoser G, Shaughnessy AF. Spironolactone in left-sided heart failure: how does it fit in?. Am Fam Physician. 2001;64:1393–9,1399

2. Stauss HM, Zhu YC, Redlich T, Adamiak D, Mott A, Kregel KC, et al. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk. 1994;1:255–62.

3. Flammang D, Waynberger M, Chassing A. Acute and long-term efficacy of perindopril in severe chronic congestive heart failure. Am J Cardiol. 1993;71:48E–56E.

4. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail. 1999;1:211–7.

5. Sami MH. Distinctive properties of perindopril among converting enzyme inhibitors in congestive heart failure. Can J Cardiol. 1994;10(Suppl D):13D–6D.

6. Thuillez C, Richard C, Loueslati H, Auzepy P, Giudicelli JF. Systemic and regional hemodynamic effects of perindopril in congestive heart failure. J Cardiovasc Pharmacol. 1990;15:527–35.

editor's note: This letter was sent to the authors of “Spironolactone in left-sided heart failure: how does it fit in?,” who declined to reply.

 

Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.


Copyright © 2002 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article